Low-dose radiation plus immunotherapy for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma that has come back after initial treatment.
- You are 18 years or older.
- Your daily functioning is fairly good (Karnofsky score of 60 or higher).
- Your blood tests show your liver, kidneys, and blood cells are working well enough.
- You are not taking more than 10 mg of prednisone (or an equivalent steroid) daily.
- You do not have an active autoimmune disease or a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This Phase 2 study tests tislelizumab (an anti–PD-1 immune therapy) combined with low-dose bevacizumab (Avastin) for recurrent glioblastoma that has already been treated with bevacizumab. If you qualify, you may be offered a new combination approach aimed at slowing tumor growth.
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.